The chief executive officer of Graphite Bio discusses the phase 1/2 CEDAR trial of GPH101, an investigative Cas9-edited autologous CD34+ cell therapy for the treatment of sickle cell disease.
CGTLive Staff
Advertisement
Articles by CGTLive Staff
Review top news and interview highlights from the week ending April 15, 2022.
Peter J. McAllister, MD, FAAN, presented promising data from the phase 2 STEMTRA trial at AAN 2022.
Advertisement
Advertisement
Advertisement
Trending on CGTlive®
1
Sanofi’s Neovascular Age-Related Macular Degeneration Gene Therapy SAR402663 Garners FDA Fast Track Designation
2
Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
3
Daniel Galbraith, PhD, on Using Targeted Locus Amplification to Analyze Genetically Modified Cells
4
